Clinical impact of BioFire Blood Culture Identification 2 implementation in patients with <i>Staphylococcus</i> bacteremia.

ABSTRACT: The BioFire Blood Culture Identification 2 (BCID2) PCR panel allows for rapid identification of blood pathogens, including Staphylococci other than Staphylococcus aureus (SOSA) and methicillin-susceptible S. aureus (MSSA). The objective of this study was to evaluate how BCID2 implementation impacted duration of vancomycin therapy, clinical outcomes, and rate of pharmacist intervention. This was a multi-center, retrospective study of adult patients admitted with MSSA or SOSA-positive blood cultures. The primary endpoint, days of vancomycin therapy, was compared between the pre- and post-BCID2 periods. Secondary endpoints included duration of MSSA bacteremia, hospital mortality, and pharmacist interventions. Of the 617 patients included in the primary analysis, MSSA bloodstream

SUBMITTER: Duell CH 

PROVIDER: S-EPMC12772346 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature